Cost Is the Biggest Barrier to Xdemvy Adherence

You diagnosed Demodex blepharitis. You prescribed Xdemvy (Lotilaner ophthalmic solution 0.25%) — the first and only FDA-approved treatment for the condition. Your patient was relieved to finally have an answer. Then they saw the price tag.

For providers, this scenario is frustratingly common. Xdemvy works, but only if patients can afford to fill and complete the 6-week course. A full treatment costs approximately $1,850 without insurance, and even with coverage, prior authorization delays and high copays can cause patients to abandon their prescriptions before they ever start.

This guide is a practical resource for eye care providers — ophthalmologists and optometrists — looking to help patients navigate the financial side of Xdemvy treatment. Because when cost becomes a barrier to adherence, clinical outcomes suffer.

What Your Patients Are Actually Paying

Understanding the current cost landscape helps you anticipate patient concerns and proactively address them.

Without Insurance

• 5 mL bottle: Approximately $600
• 10 mL bottle: Up to $2,034
• Typical full 6-week course: Around $1,850

With Insurance

Insurance coverage for Xdemvy has expanded significantly since launch:

• Over 85% of insured patients across commercial, Medicare Part D, and Medicaid plans now have some form of coverage
• Prior authorization is commonly required — this is the most frequent delay point
• With payer coverage and available copay assistance, the majority of insured patients pay $30 or less

The Real-World Problem

Even when coverage exists, patients encounter friction:

• Prior authorization can take days to weeks
• Specialty pharmacy coordination adds complexity
• Patients who see a high initial quoted price may never follow through
• Medicare patients cannot use manufacturer copay cards (Anti-Kickback Statute restrictions)

The provider's role in bridging this gap cannot be overstated. A brief conversation about cost at the point of prescribing — combined with active support from your team — dramatically improves fill rates.

Manufacturer Savings Programs

Tarsus Pharmaceuticals offers two primary programs to help patients afford Xdemvy. Familiarizing your staff with these programs allows for seamless enrollment at the point of care.

Xdemvy Savings Card

• Eligibility: Commercially insured patients (not available for government-funded insurance including Medicare, Medicaid, Tricare, or VA)
• Benefit: Eligible patients may pay as little as $0 copay
• Enrollment: Available at xdemvy.com/savings-and-access
• How it works: The savings card covers the difference between the patient's copay and the program maximum. It functions at the specialty pharmacy level.

Provider tip: Have your staff download or print the savings card enrollment information. Handing it to the patient before they leave the office — or better yet, helping them enroll on the spot — significantly increases utilization.

Tarsus Connect Patient Assistance Program

• Eligibility: Uninsured or underinsured patients who meet financial hardship criteria
• Benefit: May provide Xdemvy at no cost to qualifying patients
• Enrollment: Through the prescriber's office or at xdemvyhcp.com
• Documentation: Requires financial hardship documentation; the application process involves your office

Provider tip: For uninsured patients, initiate the PAP conversation proactively. Many patients don't know these programs exist and assume they simply can't afford the medication.

Tarsus Field Reimbursement Managers

Tarsus employs Field Reimbursement Managers (FRMs) who work directly with eye care practices to:

• Navigate insurance coverage and prior authorization
• Troubleshoot claim denials and appeals
• Support patient enrollment in savings programs
• Educate your staff on the latest coverage landscape

If you're prescribing Xdemvy regularly and encountering access issues, connecting with your regional FRM can streamline the process for your entire practice.

Coupon and Discount Card Options

Beyond the manufacturer programs, patients may encounter third-party discount options. Here's what to know:

Third-Party Discount Cards

Services like GoodRx, SingleCare, and RxSaver may list Xdemvy pricing, but their utility is limited for this medication because:

• Xdemvy is dispensed through specialty pharmacies only — many discount card platforms don't have strong specialty pharmacy coverage
• The cash price is high enough that even with a discount card, costs remain substantial
• The manufacturer savings card typically offers a better deal for commercially insured patients

That said, for patients who are between coverage options or have unusual insurance situations, it's worth checking these platforms as a secondary option.

Specialty Pharmacy Financial Counseling

Most specialty pharmacies that dispense Xdemvy (including CVS Specialty and Walgreens Specialty) have dedicated financial counselors who:

• Run benefits verification before dispensing
• Apply all available copay assistance automatically
• Coordinate with the manufacturer savings card
• Identify additional savings opportunities

Encourage your patients to engage with the specialty pharmacy's financial counseling team when they receive the initial outreach call.

Generic Alternatives and Therapeutic Substitution

Generic Xdemvy

There is currently no generic version of Xdemvy (Lotilaner ophthalmic solution) available. As a relatively new, patent-protected medication, generic competition is not expected in the near term.

Therapeutic Alternatives

For patients who truly cannot afford Xdemvy despite all available assistance programs, consider these alternative approaches to Demodex blepharitis management:

• Tea tree oil lid scrubs (Terpinen-4-ol): OTC eyelid cleansers are the most accessible and affordable option. Less effective than Xdemvy and requires consistent daily use, but costs under $20/month. May be a bridge therapy while financial assistance is arranged.
• Oral Ivermectin: Used off-label for Demodex. Generic Ivermectin is inexpensive (typically $10-30 for a course), but it's systemic, has more side effects, and is not FDA-approved for ocular Demodex. Requires informed consent discussion.
• BlephEx (microblepharoexfoliation): In-office procedure that mechanically removes mites and debris. Cost per session varies ($100-200+), may need to be repeated, and is not always covered by insurance.
• Intense Pulsed Light (IPL) therapy: Can reduce Demodex populations and improve meibomian gland function. Typically $300-500 per session, usually requires multiple sessions, and is rarely covered by insurance.

None of these alternatives match Xdemvy's targeted efficacy for Demodex blepharitis, but they provide options when cost is an absolute barrier. For a patient-facing comparison, you can refer patients to our guide on alternatives to Xdemvy.

Building Cost Conversations Into Your Workflow

The most effective way to prevent cost-related non-adherence is to address it proactively — before the patient leaves your office.

At the Point of Prescribing

1. Name the cost upfront: "Xdemvy can be expensive without the right support. A full course is about $1,850 without insurance, but most insured patients pay $30 or less with the savings programs we'll set up for you."
2. Introduce the savings card immediately: Don't wait for the patient to encounter sticker shock at the pharmacy. Hand them the enrollment materials or have your staff help them register before checkout.
3. Set expectations about specialty pharmacy: "This medication comes from a specialty pharmacy — they'll call you to arrange delivery. When they call, make sure to ask about their financial counseling services."

Staff Training

Your front desk and technician staff should be trained to:

• Explain that Xdemvy requires specialty pharmacy fulfillment
• Assist with manufacturer savings card enrollment
• Initiate prior authorization promptly
• Know when to escalate to the Tarsus Field Reimbursement Manager
• Follow up with patients who haven't filled within 7-10 days

Follow-Up Protocol

Consider implementing a follow-up system:

• Day 3-5 after prescribing: Check if the specialty pharmacy has contacted the patient
• Day 7-10: If the patient hasn't filled, call to identify barriers
• During the 6-week treatment: Check adherence at any scheduled visits

Patients who encounter cost barriers often don't call back to tell you — they simply don't fill. Proactive follow-up catches these patients before they fall through the cracks.

Documenting for Prior Authorization

Strong clinical documentation improves prior authorization success rates. When prescribing Xdemvy, document:

• Clinical findings consistent with Demodex blepharitis (cylindrical dandruff, collarettes, mite identification)
• Failure or inadequate response to previous treatments (OTC lid scrubs, warm compresses)
• Impact on quality of life and vision
• Medical necessity for FDA-approved Demodex-specific therapy

Resources for Your Practice

Bookmark these resources for your team:

• Xdemvy HCP Portal: xdemvyhcp.com — prescribing information, savings program enrollment, FRM contact
• Xdemvy Savings Card: xdemvy.com/savings-and-access
• Medfinder Provider Platform: medfinder.com/providers — tools to help your patients find specialty medications and navigate access

Final Thoughts

Xdemvy is a genuinely effective treatment for a condition that has lacked a targeted FDA-approved option. The clinical value is clear. The challenge is ensuring that cost doesn't stand between your diagnosis and your patient's adherence.

By integrating savings program enrollment into your prescribing workflow, training your staff on the specialty pharmacy process, and following up proactively on unfilled prescriptions, you can dramatically improve the percentage of patients who actually complete their Xdemvy course.

The conversation about cost takes two minutes. The impact on adherence — and outcomes — lasts much longer.

For more provider-focused resources on Xdemvy access and availability, see our guides on what providers need to know about Xdemvy availability and how to help patients find Xdemvy in stock.